Abstract
Objectives: Evaluation of the administered SCS dose including the calculation of the dose in 8th, 12th and 52nd week of therapy in relation to CD activity; analysis of SCS protecting effect of azathioprine in 52nd week of treatment. The study investigated patients fulfilling entry criteria: age 0-19 years, CD diagnosis, prospective evaluation of the disease activity, SCS therapy during the 1st year of observation, follow-up for at least 52 weeks. Conclusion: SCS treatment was highly effective for reaching remission and managing of relapse in pediatric Crohn disease.
Cumulative dose of administered corticosterids in the first year of therapy did not reach values which are associated with a negative influence on growth. The treatment with azathioprine is an indispensable and highly effective part of the therapy of nonspecific intestinal inflammations in children, contributes to a lower exposure to SCS and increases the probability of long-term remission.